Holen Sie sich die Stockscreener-App
5.74
2.50%
0.14
Schlusskurs vom Vortag:
$5.60
Offen:
$5.74
24-Stunden-Volumen:
215.29K
Relative Volume:
1.11
Marktkapitalisierung:
$12.75M
Einnahmen:
$895.50K
Nettoeinkommen (Verlust:
$-26.30M
KGV:
-3.50
EPS:
-1.64
Netto-Cashflow:
$-23.84M
1W Leistung:
-4.97%
1M Leistung:
+17.14%
6M Leistung:
-59.65%
1J Leistung:
-85.36%
1-Tages-Spanne:
$5.4508
$5.94
1-Wochen-Bereich:
$5.08
$6.25
52-Wochen-Spanne:
$3.65
$45.60
Mainz Biomed N V Stock (MYNZ) Company Profile
Firmenname
Mainz Biomed N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MYNZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
5.74 | 12.75M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Maxim Group | Buy |
| 2024-11-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | Eingeleitet | H.C. Wainwright | Buy |
Mainz Biomed N V Aktie (MYNZ) Neueste Nachrichten
Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire
Mainz Biomed Partners with labor team w ag to Launch ColoAlert® Colorectal Cancer Screening Test in Switzerland - Nasdaq
First DNA-Based Cancer Test Enters Swiss Market: Can Mainz Biomed Transform Screening? - StockTitan
Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group - Defense World
Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq
How To Trade (MYNZ) - Stock Traders Daily
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire
Mainz Biomed Collaborates with GANZIMMUN Diagnostics to Launch Enhanced ColoAlert Colorectal Cancer Screening Test in Germany - Nasdaq
Mainz Biomed's Revolutionary DNA Tech Powers New German Cancer ScreeningWhat Sets It Apart - StockTitan
A stock that deserves closer examination: Mainz Biomed N.V (MYNZ) - US Post News
The Future of Mainz Biomed N.V: Analyzing MYNZ - The InvestChronicle
Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Canada
Mainz Biomed regains Nasdaq compliance with equity rule - MSN
Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire
Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan
Mainz Biomed Regains Compliance with Nasdaq Listing Requirements - Nasdaq
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed Moves Forward With Pivotal CRC Study After Feasibility Trial - Nasdaq
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com
Mainz Biomed Partners with Quest Diagnostics to Advance Colorectal Cancer Screening in the U.S. - Citybuzz
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq
Mainz Biomed (MYNZ) Stock Soars In Pre-Hour Session On A New Partnership - Stocks Telegraph
Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha
Mainz Biomed partners with Quest for colorectal cancer test - Investing.com
Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire
Mainz Biomed Partners with Quest Diagnostics for Major Colorectal Cancer Screening Study - StockTitan
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline - Investing.com
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline By Investing.com - Investing.com South Africa
Mainz Biomed Secures $8 Million in Follow-On Offering - TipRanks
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewswire
Mainz Biomed Secures $8M Through Strategic Follow-on Offering with Dual-Warrant Structure - StockTitan
Mainz Biomed prices $8M offering of shares and warrants - MSN
Mainz Biomed Prices $8 Million Follow-On Offering to Boost Diagnostics Operations - TipRanks
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - The Manila Times
Mainz Biomed Announces $8M Follow-On Offering with Dual Warrant Structure - StockTitan
Mainz Biomed N.V. Announces Pricing of Follow-On Offering to Raise Approximately $8.0 Million - Nasdaq
Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga
Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com India
Mainz Biomed announces 1-for-40 reverse stock split - Medical Buyer
Mainz Biomed (NASDAQ:MYNZ) Shares Set to Reverse Split on Tuesday, December 3rd - Defense World
Mainz Biomed Announces Stock Split - GlobeNewswire
Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues | MYNZ Stock News - StockTitan
Finanzdaten der Mainz Biomed N V-Aktie (MYNZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
3.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):